ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes

Diabetologia

Volumn 47, Issue 2, 2004, Pages 316-324

  Gross M L ^a   Heiss N ^a   Weckbach, M ^a   Hansen, A ^a   El Shakmak, A ^b   Szabo, A ^b   Munter K ^c   Ritz, E ^a   Amann, K ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c BAYER AG   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

ACE inhibitor; Animal model; Capillary; Diabetes mellitus; Endothelin A receptor blocker; Endothelin 1; Fibrosis; Heart; Hyperglycaemia; Stereology

Indexed keywords

DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; TRANDOLAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE CAPILLARY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE ANALYSIS; RAT; RECEPTOR BLOCKING; STREPTOZOCIN DIABETES;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA, THORACIC; ARTERIOLES; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; COLLAGEN TYPE IV; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIN-1; FIBROSIS; GENE EXPRESSION; HEART; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INDOLES; MALE; MYOCARDIUM; PHENYLPROPIONATES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; TRANSFORMING GROWTH FACTOR BETA;

EID: 1542374737     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1309-z     Document Type: Article

References (50)

1. Fein FS, Sonnenblick EH (1994) Diabetic cardiomyopathy. Cardiovasc Drugs Ther 8:65-73
2. Fischer M, Wiest G, Tekesin I et al. (1992) Effects of combined renovascular hypertension and diabetes mellitus on myocardial cells, non-vascular interstitium and capillaries: a stereological study on rat hearts. Virchows Arch A Pathol Anat Histopathol 420:499-506
3. Standl E, Schnell O, Balletshofer B et al. (1997) Influence of diabetes mellitus on the heart and macrovascular mortality. Diabetologia 40 [Suppl 2]:S125-S126
4. Suzuki T, Kumazaki T, Mitsui Y (1993) Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun 191:823-830
5. Chua BH, Chua CC, Diglio CA, Siu BB (1998) Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1178:201-206
6. Fukuchi M, Giaid A (1998) Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts. J Cardiovasc Pharmacol 31 [Suppl 1]:S421-S423
7. Haynes WG, Ferro CJ, Webb DJ (1998) Bosentan in essential hypertension. N Engl J Med 339:346-347
8. Haynes WG, Webb DJ (1998) Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16:1081-1098
9. Rabelink TJ, Stroes ES, Bouter KP, Morrison P (1998) Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? Cardiovasc Res 39:543-549
10. Rabelink TJ, Bakris GL (1998) The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab 24:381-388
11. Disashi T, Nonoguchi H, Iwaoka T et al. (1997) Endothelin converting enzyme-1 gene expression in the kidney of spontaneously hypertensive rats. Hypertension 30:1591-1597
12. Verhaar MC, Strachan FE, Newby DE et al. (1998) Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97:752-756
13. Serneri GG, Cecioni I, Vanni S et al. (2000) Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart. Circ Res 86:377-385
14. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR (1999) Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33:306-310
15. Misurski DA, Hopfner RL, McNeill JR, Gopalakrishnan V (1999) Endothelium-dependent alterations in responses of the mesenteric vascular bed in the streptozotocin diabetic rat. Proc West Pharmacol Soc 42:49-51
16. Ficai S, Herizi A, Mimran A, Jover B (2001) Endothelin blockade in angiotensin II hypertension: prevention and treatment studies in the rat. Clin Exp Pharmacol Physiol 28:1100-1103
17. Gurbanov K, Rubinstein I, Hoffman A, Abassi Z, Better OS, Winaver J (1996) Bosentan improves renal regional blood flow in rats with experimental congestive heart failure. Eur J Pharmacol 310:193-196
18. Marin-Garcia J, Goldenthal MJ, Moe GW (2002) Selective endothelin receptor blockade reverses mitochondrial dysfunction in canine heart failure. J Card Fail 8:326-332
19. Nabokov AV, Amann K, Wessels S, Munter K, Wagner J, Ritz E (1999) Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int 55: 512-519
20. Oie E, Clausen OP, Yndestad A, Grogaard HK, Attramadal H, Oie E (2002) Endothelin receptor antagonism attenuates cardiomyocyte apoptosis after induction of ischemia in rats. Scand Cardiovasc J 36:108-116
21. Amann K, Wolf B, Nichols C (1997) Aortic changes in experimental renal failure: hyperplasia or hypertrophy of smooth muscle cells? Hypertension 29:770-775
22. Amann K, Munter K, Wessels S (2000) Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals. J Am Soc Nephrol 11:1702-1711
23. Henquell L, Odoroff CL, Honig CR (1997) Intercapillary distance and capillary reserve in hypertrophied rat hearts beating in situ. Circ Res 41:400-408
24. Buzello M, Boehm C, Orth S (2003) Myocyte loss in early left ventricular hypertrophy of experimental renovascular hypertension. Virchows Arch 442:364-371
25. Rodriguez-Porcel M, Lerman A, Ritman EL, Wilson SH, Best PJ, Lerman LO (2000) Altered myocardial microvascular 3D architecture in experimental hypercholesterolemia. Circulation 102:2028-2030
26. Kirchengast M, Munter K (1999) Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med 221:312-325
27. Weber KT, Anversa P, Armstrong PW et al. (1992) Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 20:3-16
28. Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G, Sriram K (1993) Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 88 [Suppl 1]: 107-124
29. Weber KT, Brilla CG (1993) Structural basis for pathologic left ventricular hypertrophy. Clin Cardiol 16:II10-II14
30. Riva E, Andreoni G, Bianchi R (1998) Changes in diastolic function and collagen content in normotensive and hypertensive rats with long-term streptozotocin-induced diabetes. Pharmacol Res 37:233-240
31. Candido R, Forbes JM, Thomas MC et al. (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92:785-792
32. Ayaz M, Can B, Ozdemir S, Turan B (2002) Protective effect of selenium treatment on diabetes-induced myocardial structural alterations. Biol Trace Elem Res 89:215-226
33. Dhein S, Hochreuther S, Aus Dem Spring C, Bollig K, Hufnagel C, Raschack M (2000) Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. J Pharmacol Exp Ther 293:351-359
34. Cavasin MA, Carretero OA, Yang F, Oja-Tebbe N, Peng H, Yang XP (2002) Long-term effects of selective and nonselective endothelin receptor antagonists in mice with heart failure. J Card Fail 8:254-261
35. Basso C, Thiene G, Della Barbera M, Angelini A, Kirchengast M, Iliceto S (2002) Endothelin A-receptor antagonist administration immediately after experimental myocardial infarction with reperfusion does not affect scar healing in dogs. Cardiovasc Res 55:113-121
36. Mathiesen ER, Borch-Johnsen K, Jensen DV, Deckert T (1989) Improved survival in patients with diabetic nephropathy. Diabetologia 32:884-886
37. Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN (2001) Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158:1653-1663
38. Woods LL, Mizelle HL, Hall JE (1987) Control of renal hemodynamics in hyperglycemia: possible role of tubuloglomerular feedback. Am J Physiol 252:F65-F73
39. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ (2002) Hyperglycemia- induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51:1938-1948
40. Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, Remuzzi G (1998) Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47:450-456
41. Nabokov A, Amann K, Wagner J, Gehlen F, Munter K, Ritz E (1996) Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant 11:514-520
42. Witte K, Reitenbach I, Stolpe K, Schilling L, Kirchengast M, Lemmer B (2003) Effects of the endothelin a receptor antagonist darusentan on blood pressure and vascular contractility in type 2 diabetic Goto-Kakizaki rats. J Cardiovasc Pharmacol 41:890-896
43. Verma S, Maitland A, Weisel RD et al. (2002) Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: reversal with endothelin antagonism. J Thorac Cardiovasc Surg 123:1120-1124
44. Vesci L, Mattera GG, Tobia P, Corsico N, Calvani M (1995) Cardiac and renal endothelin-1 binding sites in streptozotocin-induced diabetic rats. Pharmacol Res 32:363-367
45. Crespo MJ, Moreta S, Gonzalez J (2003) Cardiovascular deterioration in STZ-diabetic rats: possible role of vascular RAS. Pharmacology 68:1-8
46. Fiordaliso F, Li B, Latini R (2000) Myocyte death in streptozotocin- induced diabetes in rats in angiotensin II-dependent. Lab Invest 80:513-527
47. Park JB, Schiffrin EL (2001) ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 37:1444-1449
48. Zoja C, Orisio S, Perico N (1991) Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue. Lab Invest 64:16-20
49. Kurihara H, Yoshizumi M, Sugiyama T et al. (1998) Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 159:1435-1440
50. Gilbert RE, Rumble JR, Cao Z (2000) Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circ Res 86:158-165